Background: Coronary artery disease (CAD) has high morbidity and mortality rates. Coronary angioplasty and antiplatelet therapy with acetylsalicylic acid (ASA) are critical in treating CAD patients. Elective angioplasty lacks studies on the factors associated with resistance to ASA. Objective: To evaluate the prevalence and ASA resistance related factors in patients undergoing elective angioplasty. Methods: Retrospective cohort study of 198 patients undergoing elective angioplasty, evaluated for resistance to ASA by optical aggregometry with arachidonic acid as agonist. Results: Resistance to ASA in 6.56% of the cohort (13/198). C-reactive protein (CRP) levels indicated association with resistance to ASA (p=0.02). Conclusions: Low prevalence of ASA resistance in patients undergoing elective angioplasty; C-reactive protein high levels are related to greater frequency of this resistance.
Introduction
Coronary artery disease (CAD) is the leading cause of death in the world 1 ; in Brazil, it accounts for 28.9% of all deaths 2 . In stable CAD, the use of acetylsalicylic acid (ASA) in patients undergoing elective percutaneous c o r o n a r y i n t e r v e n t i o n ( P C I ) i s a g r a d e o f recommendation I, and level of evidence A 3 . For these patients, resistance to ASA is related to the worst outcome possible 4 . Therefore, a better understanding of the factors associated with ASA resistance is required.
ASA resistance or a high platelet reactivity to ASA or a non-response to ASA are common names for the same laboratory phenomenon, which can set a higher incidence of treatment failure related to this antiplatelet 5 . Treatment failure is a broader phenomenon, which refers to cases in which, even with proper use of the antiplatelet, the patient suffers a cardiovascular event potentially preventable by the use of antiplatelet 6 .
The concept of non-response to ASA was introduced in early 90's, based on studies with patients with prior encephalic vascular accident 7, 8 . These studies evidenced the frequent occurrence of cardiovascular outcomes, such as nonfatal myocardial infarction, in non-responsive patients. Recent studies confirmed such findings, proving that ASA resistance determines worse prognosis even in patients with stable CAD 4, 9 .
The effects of this antiplatelet can be evaluated by quantification methods of ASA resistance; dosage of thromboxane A2 (TXA2) metabolism byproducts, or by quantification of the cyclooxygenase-1 (COX1) blocking degree, either by optical aggregometry, impedance or flow cytometry 10 .
Correlation between the different methods is low, with prevalence of resistance to ASA ranging from 60% to less than 4% in different methods 11 . Among them, optical aggregometry, which uses arachidonic acid as agonist at a concentration of 0.5 mg/mL, is the test less influenced by laboratory and genetic variability. Thus, today it is the gold standard for the study of ASA resistance [12] [13] [14] .
Nevertheless, the intratest variability is great in most tests, occurring to a lesser extent with blood dosage of TXA2 15 .
In the study with stable CAD patients, resistance to 
Results
Thirteen patients were resistant to ASA, representing 6.56% of the cohort (13/198 Resistance to ASA was not a predictor of any of these characteristics.
As for laboratory data, blood glucose and platelet levels were not associated with the occurrence of ASA resistance. It was observed, however, a statistically significant association between ASA resistance and greater CRP values (p=0.02).
Discussion
Hamberg et al. 17 and Smith et al. 18 , in 1974, discovered the role of prostaglandins, particularly of one of their derivatives: thromboxane A2 in thrombus formation. Weiss et al. 19 , O'Brien 20 , Zucker and Peterson 21 have defined the antiplatelet action of ASA, a non-steroidal anti-inflammatory, inhibitor of TXA2 formation, and initially used only as analgesic. Studies by Fitzgerald et al. 22 and Patrignani et al. 23 defined the ASA mechanism in blocking the synthesis of TXA2. They have also determined that using 70-100 mg/day would be enough to inhibit the most selective platelet COX1 22, 23 .
Over time, it was found that the use of ASA was critical in the treatment of several medical conditions related to atherosclerosis. In a meta-analysis from 2002 24 ASA -acetylsalicylic acid; AMI -acute myocardial infarction; CABG -coronary artery bypass graft surgery; PCI -percutaneous coronary intervention; SAH -systemic arterial hypertension; DM -Diabetes mellitus; COPD -chronic obstructive pulmonary disease; PPI -proton pump inhibitor; CRP -C-reactive protein; SD -standard deviation improve antiplatelet therapy with this drug. Among the several points raised, understanding the importance of resistance to ASA still remains a major topic for many studies.
In a study on the resistance to ASA, 326 patients of a stable CAD cohort, taking 325 mg/day of aspirin for at least seven days, were tested through optical aggregometry using adenosine and arachidonic acid as agonists 4 . In that study, the resistance was detected in 5.2% of patients, who showed higher rates of composite outcome consisting of death, AMI and EVA in 1.9 years (OR: 4.14) .
In this study, the prevalence of resistance to ASA was 6.56%, a value close to others found in medical literature; however, the degree of adherence was not evaluated. But a study that evaluated ASA resistance before and after a period of monitoring the adherence to treatment did not detect differences in resistance rates in both periods evaluated 25 .
Such non-response can be explained by several possible reasons. Although they do not yet have their role on ASA resistance well established, some genetic characteristics seem to explain some cases of nonresponse 26 . In an in vitro resistance analysis through optical aggregometry with arachidonic acid as agonist, patients undergoing elective PCI showed 3.4% of resistance to the use of ASA (7/203). However, of resistant patients, 6 admitted not using ASA as recommended, i.e., only 1 (0.4%) proved to be truly resistant 27 . The use of enteric-coated aspirin increases the chance of a patient being identified as resistant after a first dose, but this chance almost becomes void if the patient does prolonged use of such aspirin formulation 28 .
In a study evaluating the resistance to ASA in 900 patients with stable CAD, through VerifyNow ® test and Multiplate Analyzer ® , type 2 diabetes, previous myocardial infarction, smoking, and previous coronary bypass surgery were independent determinants for the occurrence of resistance to ASA 29 . These relations were not observed in this study, which used the optical aggregometry, still the gold standard for the study of ASA resistance 10 .
The relationship of inflammation with resistance to ASA is still an emerging field of study. Larsen et al. 30 revealed a relationship between higher levels of C-reactive protein and the highest tertile resistance evaluated by VerifyNow ® and Multiplate Analyzer ® tests. This cohort also observed that higher levels of CRP are related with greater chance of ASA resistance. High levels of CRP determine the worst prognosis in patients suffering from cardiovascular diseases with atherothrombotic pathophysiology, but the exact explanation of this is still controversial 31 . The association of high levels of CRP with resistance to ASA, a drug of widely recognized benefit in preventing outcomes among that profile of patients, can raise a hypothesis for understanding the role of inflammation as a determinant of poor prognosis of atherothrombotic cardiovascular diseases.
This study has some limitations: its retrospective character reduces the statistical power of associations found; it was developed based on data from a single institution, limiting the ability to generalize any conclusion here found. In addition, there has been no evaluation of inter and intraobserver variability in the collection of angiographic data, although this collection has been made by experienced hemodynamicists.
Nevertheless, the study provides information that add up to the knowledge about the factors associated with variability in response to ASA in patients with stable CAD.
Conclusions
The prevalence of ASA resistance in patients undergoing elective percutaneous coronary intervention is low; high levels of CRP relate to greater frequency of such resistance. Further studies are needed to better understand the associations found in this study.
